cas 2649469-21-4|| where to buy ethyl cis-4,5-dimethyl-3-oxo-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate

Produktname:ethyl cis-4,5-dimethyl-3-oxo-5-(trifluoromethyl)tetrahydrofuran-2-carboxylate

IUPAC Name:ethyl (4R,5R)-4,5-dimethyl-3-oxo-5-(trifluoromethyl)oxolane-2-carboxylate

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM1051523-1g	in stock	șǺƩ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2649469-21-4 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:2649469-21-4; Molekulare Formel:C10H13F3O4; Schmelzpunkt:-; SMILES-Code:CCOC(=O)C1O[C@@]([C@H](C1=O)C)(C)C(F)(F)F; Dichte:

: Katalognummer:CM1051523; Molekulargewicht:254.21; Siedepunkt:; Mdl-Nr.:; Lagerung:

: Tetrahydrofurans; Tetrahydrofuran is a heterocyclic organic compound with the molecular formula C4H8O. Tetrahydrofuran belongs to ethers and is the complete hydrogenation product of furan. It is a colorless, water-miscible organic liquid with small viscosity at normal temperature and pressure. Because of its long liquid range, it is a commonly used medium polar aprotic solvent. Its main use is as a precursor of high molecular polymers.

: VX-548; Vertex announced positive results from its Phase 2 dose-ranging study of VX-548 in people with painful diabetic peripheral neuropathy (DPN). VX-548 is an investigational oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system. NaV1.8 is a genetically validated target for the treatment of pain. Vertex's strategy is to develop new drug types by selectively inhibiting NaV1.8. Compared to opioid drugs, they may provide better analgesic effects while avoiding side effects such as addiction. VX-548 has been granted Breakthrough Therapy and Fast Track designations in the U.S. for moderate to severe acute pain.